-
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Read articlePer Fransson, PhD, Per Nilsson, PhD, Adalsteinn Gunnlaugsson, MD, Lars Beckman, MD, Björn Tavelin, BSc, David Norman, BSc, Camilla Thellenberg-Karlsson, MD, Prof Morten Hoyer, MD, Magnus Lagerlund, MD, Jon Kindblom, MD, Claes Ginman, MD, Bengt Johansson, MD, Kirsten Björnlinger, MD, Mihajl Seke, MD, Måns Agrup, MD, Prof Björn Zackrisson, MD, Elisabeth Kjellén, MD, Prof Lars Franzén, MD, Prof Anders Widmark, MD
-
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Read articleDavid Dearnaley et al.
